Terminal › Stocks › XAIR

Beyond Air, Inc. (XAIR) Stock

Healthcare · Medical - Devices · US

$0.63 -20.04%

Last updated Jun 19, 2026 00:00 UTC

XAIR Key Statistics

Market Cap$3.19M

P/E (TTM)-0.12

P/S (TTM)0.46

P/B (TTM)0.66

Revenue (TTM)$6.92M

EPS (TTM)$-5.42

Dividend Yield—

ROE (TTM)-279.58%

Net Margin-447.73%

Gross Margin1.82%

52W High$0.95

52W Low$0.61

Analyst ViewBuy

Price Target$1.00

Employees107

Volume695,258

About Beyond Air, Inc.

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

CEO: Amir Avniel. Company website

See XAIR live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open XAIR in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.